Overview

• The phase 2b trial randomized 198 adults with moderate to severe generalized anxiety disorder to single doses of 25, 50, 100 or 200 micrograms of MM120 or placebo across 22 U.S. sites, with supervised dosing and no psychotherapy.
• At 12 weeks, 65% of participants on 100 micrograms showed improvement versus 30.8% on placebo, with remission rates of 47.5% and 20% respectively.
• Symptom relief appeared within a day at higher doses and persisted through three months, supporting a dose-dependent effect with 100 micrograms selected for further study.
• Acute effects on dosing day were common and transient — perceptual changes, nausea and headaches — typically resolving within about 12 hours, with patients monitored during the session.
• Experts noted compromised blinding and participant dropouts, and larger phase 3 trials (Voyage and Panorama) are underway to test durability and generalizability, with key readouts expected in 2026.